Trials (University Cancer Institute Toulouse-Oncopole) - Revision history

Francine at 18:42, 14 December 2025

2025-12-14T18:42:13Z

← Older revision		Revision as of 18:42, 14 December 2025
Line 4:		Line 4:
	<span style="display:none">francecountry</span>		<span style="display:none">francecountry</span>
	Go back to [[University Cancer Institute Toulouse-Oncopole]] page		Go back to [[University Cancer Institute Toulouse-Oncopole]] page

			=== Trials: How to participate ===
			'''Contact information:''' [https://www.iuct-oncopole.fr/en/clinical-research Click here to access].


	'''NCTID''': NCT06112314		'''NCTID''': NCT06112314
Line 719:		Line 723:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:42:32Z

Update categories.

← Older revision		Revision as of 12:42, 6 December 2025
Line 698:		Line 698:
	<span style="display:none">hasTrialTitle::A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes</span>		<span style="display:none">hasTrialTitle::A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes</span>
	<span style="display:none">hasTrialTitle::Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma</span>		<span style="display:none">hasTrialTitle::Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma</span>
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Francine at 20:50, 2 December 2025

2025-12-02T20:50:58Z

← Older revision		Revision as of 20:50, 2 December 2025
Line 2:		Line 2:
	<span style="display:none">forproviders</span>		<span style="display:none">forproviders</span>
	<span style="display:none">forresearchers</span>		<span style="display:none">forresearchers</span>
			<span style="display:none">francecountry</span>
	Go back to [[University Cancer Institute Toulouse-Oncopole]] page		Go back to [[University Cancer Institute Toulouse-Oncopole]] page

Lucas: Update categories.

2025-12-02T14:01:06Z

Update categories.

@@ Line 1: / Line 1: @@
-{{forpatients}}
+<span style="display:none">forpatients</span>
-{{forproviders}}
+<span style="display:none">forproviders</span>
-{{forresearchers}}
+<span style="display:none">forresearchers</span>
 Go back to [[University Cancer Institute Toulouse-Oncopole]] page
@@ Line 634: / Line 634: @@
   '''Recruitment Status''': RECRUITING
   '''Condition''': Relapsed/Refractory Multiple Myeloma

Francine at 18:19, 4 January 2024

2024-01-04T18:19:05Z

Show changes

Francine: Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to University Cancer Institute Toulouse-Oncopole page '''NCTID''': NCT06112314 '''Title''': IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) '''Study Summary''': This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced mel..."

2023-12-01T22:10:35Z

Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to University Cancer Institute Toulouse-Oncopole page '''NCTID''': NCT06112314 '''Title''': IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) '''Study Summary''': This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced mel..."

Show changes